People with a movement disorder rated their health 13.1 points higher after 24 weeks of treatment.
Neurocrine Biosciences' analysis found a 6-point increase on the EQ-VAS as a threshold for clinically meaningful change in tardive dyskinesia patients treated with INGREZZA. The KINECT-PRO study showed a 13.1-point improvement in EQ-VAS scores after 24 weeks, exceeding the threshold. The findings will be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference.
How this was made
The 30-second read
Why it matters
The fresh efficacy metrics could reinforce NBIX's valuation and support future pricing or formulary decisions.
Market read
New clinical data may prompt short‑term buying interest in NBIX.
What to watch
Potential reimbursement challenges and competition from deutetrabenazine.
Background
Neurocrine Biosciences (NBIX) detailed a new 6‑point EQ‑VAS threshold and highlighted a 13.1‑point health‑score gain from its valbenazine (INGREZZA) Phase 4 study.
Ticker impact
Neurocrine Biosciences presented new analysis of its Phase 4 KINECT-PRO study showing a 13.1‑point EQ‑VAS improvement at Week 24.
likely upward pressure as market prices in the new efficacy data.
Phase 4 data confirming clinically meaningful improvement supports the drug's market potential.
Market effects
Strengthens the tardive dyskinesia treatment segment and may benefit peers with VMAT2 inhibitors.
US biotech sector could see modest uplift.
Limited to investors focused on neuro‑psychiatric therapeutics.
Counterpoint
Some may argue the data is incremental and already priced in, limiting upside.
Key entities
- companyNeurocrine Biosciences
Developer of INGREZZA for tardive dyskinesia.
- drugINGREZZA
Valbenazine capsule used to treat TD.
